课题基金 / 基金详情

项目摘要

项目成果

Hyung Joon Chun的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):肺动脉高压(PAH)是一种以肺小动脉血管重构为特征的疾病,包括由增生内皮细胞组成的丛状和同心病变的形成。我们最近发现,由配体apelin和受体APJ组成的G蛋白偶联受体信号轴的破坏导致小鼠缺氧诱导的肺动脉高压(PH)显著恶化,并发现该途径在临床PAH中也受到干扰。为了进一步表征apelin-APJ信号可能利用的下游内皮靶点,以防止PAH中的重塑过程,我们对apelin、APJ或两者均被敲低的肺动脉内皮细胞(PAECs)进行了microRNA (miRNA)阵列分析。我们确定了两个mirna (miR-424和miR-503)在PAECs中高表达,但在apelin/APJ敲低的情况下显著下调。值得注意的是,这些mirna在实验性大鼠PH模型以及临床诊断为PAH的患者分离的PAECs中也明显减少。我们的体外功能研究表明,miR-424和miR-503都具有抗增殖、抗血管生成的作用,其机制至少部分涉及FGF信号通路的靶向。我们发现,通过鼻内慢病毒递送恢复单苦杏仁碱诱导的PH模型中miR-424/503的表达可以显著改善疾病的严重程度。基于这些初步数据,我们假设miR-424/503在维持肺血管稳态中起关键作用,其表达的破坏对内皮细胞异常增殖起关键作用,而内皮细胞异常增殖是PAH的一个标志。为了进一步评估miR-424/503在PAH中的作用,我们提出以下目标:1)确定miR-424/503在PAECs中的转录调控机制,该机制涉及通过apelin-APJ信号通路靶向myocyte-specific enhancer factor 2 (MEF2); 2)评估miR-424/503在PH实验模型中的内皮特异性表达效果;3)进一步验证miR-424/503在临床PAH中的作用。
英文摘要
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a disease characterized by the vascular remodeling of the pulmonary arterioles, including formation of plexiform and concentric lesions comprised of proliferative endothelial cells. We recently found that disruption of the G protein-coupled receptor signaling axis comprised of the ligand apelin and the receptor APJ leads to significant worsening of hypoxia induced pulmonary hypertension (PH) in mice, and found that the pathway is also perturbed in clinical PAH. To further characterize the downstream endothelial targets which may be utilized by apelin-APJ signaling to protect against the remodeling processes in PAH, we carried out a microRNA (miRNA) array analysis of pulmonary artery endothelial cells (PAECs) subjected to knockdown of apelin, APJ, or both. We identified two miRNAs (miR-424 and miR-503) that are highly expressed in PAECs, but are significantly downregulated in the context of apelin/APJ knockdown. Remarkably, these miRNAs are also markedly decreased in the experimental monocrotaline rat model of PH, as well as in PAECs isolated from patients with clinically diagnosed PAH. Our in vitro functional studies demonstrated that both miR-424 and miR-503 exert anti-proliferative, anti-angiogenic effects, via a mechanism that at least in part involves targeting of the FGF signaling pathway. We found that restoration of miR-424/503 expression in the monocrotaline induced model of PH by intranasal lentiviral delivery can significantly ameliorate the severity of the disease. Based o these preliminary data, we hypothesize that miR-424/503 play a critical role in maintaining pulmonary vascular homeostasis, and that disruption of their expression serves a critical contribution to the aberrant endothelial proliferation which is a hallmark of PAH. We propose the following aims to further evaluate the role of miR-424/503 in PAH: 1) Determine the transcriptional regulatory mechanisms of miR-424/503 in PAECs that involves targeting of the myocyte-specific enhancer factor 2 (MEF2) by apelin-APJ signaling, 2) Evaluate the efficacy of endothelial specific expression of miR-424/503 in experimental models of PH, and 3) Further validate the role for miR-424/503 in clinical PAH.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of Endothelial Regulation of Fatty Acid Uptake in Metabolic Dysfunction
  • 批准号:
    10222759
  • 项目类别:
  • 资助金额:
    $52.86万
  • 财政年份:
    2018
  • 负责人:
    Hyung Joon Chun
  • 依托单位:
Molecular Mechanisms of Neonatal Pulmonary Hemorrhage
  • 批准号:
    9565805
  • 项目类别:
  • 资助金额:
    $54.94万
  • 财政年份:
    2017
  • 负责人:
    Hyung Joon Chun
  • 依托单位:
Role of MicroRNAs 424 and 503 in Pulmonary Arterial Hypertension
  • 批准号:
    8889297
  • 项目类别:
  • 资助金额:
    $41.0万
  • 财政年份:
    2012
  • 负责人:
    Hyung Joon Chun
  • 依托单位:
Role of MicroRNAs 424 and 503 in Pulmonary Arterial Hypertension
  • 批准号:
    8397188
  • 项目类别:
  • 资助金额:
    $41.5万
  • 财政年份:
    2012
  • 负责人:
    Hyung Joon Chun
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.5万元
  • 批准年份:
    2019
  • 负责人:
    王斐斐
  • 依托单位: